SK Bioscience Reports 3Q Revenue of 231.8 Billion KRW... Operating Profit Turns Positive

SK Bioscience announced on the 26th that its provisional consolidated operating results for the third quarter of this year were sales of 231.826 billion KRW and operating profit of 60.937 billion KRW. Compared to the same period last year, sales grew by 154.6%, and operating profit successfully turned positive.

At SK Bioscience L House in Andong-si, Gyeongbuk, inspection and packaging work for the influenza vaccine 'Skycellflu' is underway.
[Photo by SK Bioscience]

The company explained the background of this turnaround to profitability, stating, "Settlement amounts were received following the termination of the contract manufacturing organization (CMO) business with Novavax, and strong sales of the shingles vaccine 'Skyzoster' continued." They added, "With the resumption of production of the influenza vaccine 'Skycellflu,' which had been halted during the COVID-19 period, the company entered the National Immunization Program (NIP) market, generating sales and contributing to the turnaround to profitability."

However, the cumulative results for this year show sales of 278.91 billion KRW and an operating loss of 3.56 billion KRW, representing an 11.9% decrease in sales compared to last year and a shift to an operating loss.

This content was produced with the assistance of AI translation services.